Trial · NCT05665595
Adverse events302
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 302
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hyperthyroidism | Endocrine disorders | Pembrolizumab/Vibostolimab | 88 | 698 | 97 |
| other | Hyperthyroidism | Endocrine disorders | Pembrolizumab | 80 | 700 | 82 |
| other | Hypothyroidism | Endocrine disorders | Pembrolizumab/Vibostolimab | 66 | 698 | 67 |
| other | Hypothyroidism | Endocrine disorders | Pembrolizumab | 64 | 700 | 65 |
| other | Diarrhoea | Gastrointestinal disorders | Pembrolizumab/Vibostolimab | 66 | 698 | 80 |
| other | Diarrhoea | Gastrointestinal disorders | Pembrolizumab | 71 | 700 | 89 |
| other | Nausea | Gastrointestinal disorders | Pembrolizumab/Vibostolimab | 47 | 698 | 55 |
| other | Nausea | Gastrointestinal disorders | Pembrolizumab | 58 | 700 | 73 |
| other | Asthenia | General disorders | Pembrolizumab/Vibostolimab | 35 | 698 | 42 |
| other | Asthenia | General disorders | Pembrolizumab | 19 | 700 | 21 |
| other | Fatigue | General disorders | Pembrolizumab/Vibostolimab | 131 | 698 | 148 |
| other | Fatigue | General disorders | Pembrolizumab | 144 | 700 | 166 |
| other | Alanine aminotransferase increased | Investigations | Pembrolizumab/Vibostolimab | 68 | 698 | 79 |
| other | Alanine aminotransferase increased | Investigations | Pembrolizumab | 69 | 700 | 80 |
| other | Aspartate aminotransferase increased | Investigations | Pembrolizumab/Vibostolimab | 64 | 698 | 73 |
| other | Aspartate aminotransferase increased | Investigations | Pembrolizumab | 52 | 700 | 60 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Pembrolizumab/Vibostolimab | 75 | 698 | 97 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Pembrolizumab | 69 | 700 | 80 |
| other | Headache | Nervous system disorders | Pembrolizumab/Vibostolimab | 61 | 698 | 70 |
| other | Headache | Nervous system disorders | Pembrolizumab | 48 | 700 | 58 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05665595/events